Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo Qvantig
nivolumab and hyaluronidase-nvhy · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with specified solid tumor indications already approved for IV nivolumab, as monotherapy, maintenance after IV nivolumab plus ipilimumab, or with designated chemotherapy or cabozantinib. Concurrent IV ipilimumab is not part of this approval.
LAMPGEN ANALYSIS
Why it matters
The subcutaneous formulation offers another route across multiple tumor types. Its supporting pharmacokinetic comparison was conducted in renal cell carcinoma.
What research teams should watch
Update route-specific orders and chair planning; verify the complete regimen before switching a patient from IV nivolumab.
PRIMARY RECORDS